ArticleIndian pediatrics2026
Seroprotection Against Mumps in MMR Vaccinated Children Aged 9-12 Years: A Cross-Sectional Study.
Article in Indian pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectivesTo estimate the proportion of children aged 9-12 years with seroprotective antibody titers against mumps following a single dose of measles-mumps-rubella (MMR) vaccine administered in early childhood, and to explore the association between seroprotection and clinicodemographic profile.
methodsA cross-sectional study was conducted at a tertiary hospital in Delhi between April 2024 and August 2025. Children aged 9-12 years with a documented receipt of a single dose of MMR vaccine at 16-24 months of age were recruited. Two mL of venous blood was collected and analyzed for serum mumps-specific IgG antibodies using enzyme-linked immunosorbent assay (ELISA), with seroprotection defined as mumps antibody titers ≥ 22 RU/mL. The association between seroprotection and demographic and clinical variables, including age, sex, age at vaccination, and nutritional status, was assessed using the chi-square test or Fisher's exact test.
resultsEighty-six children (48% males) aged 9-12 years [mean (SD) 10.35 (1.04) years] were enrolled. Overall, 84.8% demonstrated seroprotective antibody titers against mumps. The median (q1, q3) mumps-specific IgG titer was 97.6 (46.1, 144.9) RU/mL. Children aged > 10 years were significantly more likely to be seronegative compared to younger children (OR 3.99, 95% CI 1.07, 14.92, P = 0.039).
conclusionNearly 85% of children who had received a single MMR dose at 16-24 months of age had seroprotective mumps antibody titers at 9-12 years. The findings highlight the need for larger community-based studies on the durability of mumps immunity and add to the accumulating evidence informing future MMR vaccination strategies in India.
Indexed as
Identifiers
42530857What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.